LEENO Industrial (A058470) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 Jul, 2026Executive summary
Revenue for Q1 2026 was KRW 99.77 billion, with operating income of KRW 47.3 billion and net income of KRW 40.4 billion, reflecting strong profitability.
The company maintains a leading position in semiconductor test equipment and medical device components, with 64.1% of sales from IC test sockets and 10.5% from medical device parts.
No borrowings were reported, and the company continues to operate with a zero debt-to-equity ratio.
Financial highlights
Q1 2026 revenue: KRW 99.77 billion, up from KRW 78.41 billion in Q1 2025.
Operating income: KRW 47.3 billion; net income: KRW 40.4 billion; basic EPS: KRW 532.
Gross margin for Q1 2026 was 51.6%.
Cash and cash equivalents at quarter-end: KRW 71.8 billion.
Dividend payout ratio for 2025 was 39.96%, with a cash dividend of KRW 800 per share.
Outlook and guidance
The company plans to maintain a dividend payout ratio of around 30-40% of net income.
Ongoing investments in new production facilities and R&D are expected to enhance capacity and competitiveness.
Latest events from LEENO Industrial
- Q1 2025 delivered strong profits, robust exports, and a debt-free position, with major facility investment.A058470
Q1 202514 Jul 2026 - Revenue and profit rose, margins remained high, and major expansion was funded internally.A058470
Q4 202414 Jul 2026 - H1 2025 net income was KRW 70.5B on KRW 190.9B revenue, with zero debt and robust exports.A058470
Q2 202514 Jul 2026 - H1 2024 net income margin exceeded 40% on ₩125.8B sales, with zero debt and strong exports.A058470
Q2 202414 Jul 2026 - Revenue and profit surged on strong semiconductor and medical device demand, with zero debt.A058470
Q4 202514 Jul 2026 - 2024 Q3 YTD revenue and profit fell, but zero debt and robust R&D support future growth.A058470
Q3 202414 Jul 2026 - Strong export-driven growth, high margins, and major factory investment with zero debt.A058470
Q3 202514 Jul 2026